Neurogene Inc. Files 8-K: Officer/Director Changes & Compensation
Ticker: NGNE · Form: 8-K · Filed: Apr 20, 2026 · CIK: 0001404644
Sentiment: neutral
Topics: corporate-governance, officer-changes, disclosure
TL;DR
Neurogene filed an 8-K detailing officer/director changes and compensation. Keep an eye on this.
AI Summary
Neurogene Inc. filed an 8-K on April 20, 2026, reporting changes in its officers and directors, along with compensatory arrangements. The filing also includes a Regulation FD disclosure and financial statements/exhibits.
Why It Matters
Changes in key personnel and their compensation can signal shifts in company strategy or financial health, impacting investor confidence.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting standard corporate events and disclosures, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- Neurogene Inc. (company) — Filer
- 0001404644 (company) — CIK
- 2026-04-20 (date) — Filing Date
FAQ
What specific changes were made regarding officers and directors?
The filing indicates Item 5.02 pertains to the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers', suggesting changes in these roles.
What is the purpose of the Regulation FD Disclosure mentioned?
Item 7.01 of the 8-K covers Regulation FD Disclosure, which is used to ensure that material non-public information is disseminated to the public in a fair and timely manner.
What types of exhibits are included with this filing?
The filing includes exhibits such as a press release (EX-99.1), and various XBRL documents for financial reporting.
When was this 8-K filing accepted by the SEC?
The filing was accepted on April 20, 2026, at 07:32:05.
What is Neurogene Inc.'s primary business sector?
Neurogene Inc. is listed under SIC code 2834, which corresponds to Pharmaceutical Preparations, and is categorized under 'Life Sciences'.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 20, 2026 regarding Neurogene Inc. (NGNE).